Ipsen S.A. (OTCMKTS:IPSEY) Sees Significant Drop in Short Interest

Ipsen S.A. (OTCMKTS:IPSEY) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totalling 100 shares, a decrease of 75.0% from the June 30th total of 400 shares. Based on an average trading volume of 1,200 shares, the short-interest ratio is currently 0.1 days.

Ipsen Price Performance

Shares of OTCMKTS IPSEY traded up $0.41 during mid-day trading on Friday, hitting $28.30. The company had a trading volume of 344 shares, compared to its average volume of 490. The stock’s 50-day moving average price is $31.46 and its 200-day moving average price is $30.04. Ipsen has a 1 year low of $26.97 and a 1 year high of $34.34.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.